The Percentage of PD-L1 Besides 50% Positivity Predicts Objective Response to Pembrolizumab in Non-Small Cell Lung Cancer

被引：0
|
作者：
Poma, A. [1 ]
Pasquini, G. [2 ]
Bruno, R. [3 ]
Ali, G. [3 ]
Proietti, A. [3 ]
Pecora, I. [2 ]
Petrini, L. [2 ]
Vasile, E. [2 ]
Chella, A. [4 ]
Fontanini, G. [1 ]
机构：
[1] Univ Pisa, Dept Surg Med Mol Pathol & Crit Area, Pisa, Italy
[2] Azienda Osped Univ Pisana, Med Oncol, Pisa, Italy
[3] Univ Hosp Pisa, Anat Pathol Unit, Pisa, Italy
[4] Azienda Osped Univ Pisana, Pneumo Oncol, Pisa, Italy
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
lung cancer; PD-L1; immunotherapy;
D O I：
10.1016/j.jtho.2019.08.969
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.04-66
引用
收藏
页码：S466 / S467
页数：2
相关论文
共 50 条
  • [11] Biomarkers predictive of PD1/PD-L1 immunotheraphy in non-small cell lung cancer
    Lupo, A.
    Alifano, M.
    Wislez, M.
    Boulle, G.
    Velut, Y.
    Biton, J.
    Cremer, I.
    Goldwasser, F.
    Leroy, K.
    Damotte, D.
    REVUE DE PNEUMOLOGIE CLINIQUE, 2018, 74 (05) : 339 - 350
  • [12] Spatial heterogeneity of PD-L1 expression and the risk for misclassification of PD-L1 immunohistochemistry in non-small cell lung cancer
    Dori, Shani Ben
    Aizic, Asaf
    Sabo, Edmond
    Hershkovitz, Dov
    LUNG CANCER, 2020, 147 : 91 - 98
  • [13] Molecular regulatory network of PD-1/PD-L1 in non-small cell lung cancer
    Zhu, Lingling
    Lin, Jiewei
    Wang, Li
    Yan, Danli
    Zhou, Jie
    Li, Wen
    Pu, Dan
    Peng, Lei
    Zhou, Qinghua
    PATHOLOGY RESEARCH AND PRACTICE, 2020, 216 (04)
  • [14] Quantification of PD-L1 expression in non-small cell lung cancer
    Verma, Vivek
    Chang, Joe Y.
    TRANSLATIONAL CANCER RESEARCH, 2017, 6 : S402 - S404
  • [15] Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non-small cell lung cancer
    Shien, Kazuhiko
    Papadimitrakopoulou, Vassiliki A.
    Wistuba, Ignacio I.
    LUNG CANCER, 2016, 99 : 79 - 87
  • [16] PD-L1 heterogeneity in patients with non-small cell lung cancer
    Wei, Zhigang
    Fan, Linlin
    Yang, Xia
    Li, Jie
    Zhan, Xuemei
    Ye, Xin
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 (05) : E268 - E274
  • [17] PD-L1 Expression in Non-Small Cell Lung Cancer: Data from a Referral Center in Spain
    Saez de Gordoa, Karmele
    Lopez, Ingrid
    Marginet, Marta
    Coloma, Berta
    Frigola, Gerard
    Vega, Naiara
    Martinez, Daniel
    Teixido, Cristina
    DIAGNOSTICS, 2021, 11 (08)
  • [18] PD-L1 expression in cell-blocks of non-small cell lung cancer: The impact of prolonged fixation
    Vigliar, Elena
    Iaccarino, Antonino
    Campione, Severo
    Campanino, Maria R.
    Clery, Eduardo
    Pisapia, Pasquale
    De Luca, Caterina
    Bellevicine, Claudio
    Malapelle, Umberto
    De Dominicis, Gianfranco
    Troncone, Giancarlo
    DIAGNOSTIC CYTOPATHOLOGY, 2020, 48 (07) : 595 - 603
  • [19] Adverse Effects of Anti-PD-1/PD-L1 Therapy in Non-small Cell Lung Cancer
    Su, Chaoyue
    Wang, Hui
    Liu, Yunru
    Guo, Qiaoru
    Zhang, Lingling
    Li, Jiajun
    Zhou, Wenmin
    Yan, Yanyan
    Zhou, Xinke
    Zhang, Jianye
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [20] Efficacy of Pembrolizumab Monotherapy in Patients With or Without Brain Metastases From Advanced Non-Small Cell Lung Cancer With a PD-L1 Expression ≥50%
    Metro, Giulio
    Banna, Giuseppe Luigi
    Signorelli, Diego
    Gili, Alessio
    Galetta, Domenico
    Galli, Giulia
    Economopoulou, Panagiota
    Roila, Fausto
    Friedlaender, Alex
    Camerini, Andrea
    Christopoulou, Athina
    Cantale, Ornella
    De Toma, Alessandro
    Pizzutilo, Pamela
    Jimenez, Beatriz
    Collazo-Lorduy, Ana
    Calles, Antonio
    Baxevanos, Panagiotis
    Linardou, Helena
    Kosmidis, Paris
    Giannarelli, Diana
    Mountzios, Giannis
    Addeo, Alfredo
    JOURNAL OF IMMUNOTHERAPY, 2020, 43 (09) : 299 - 306
12345